2014
Antibacterial Resistance Leadership Group: Open for Business
Chambers HF, Bartlett JG, Bonomo RA, Chiou C, Cosgrove SE, Cross HR, Daum RS, Downing M, Evans SR, Knisely J, Kreiswirth BN, Lautenbach E, Mickley BS, Patel R, Pettigrew MM, Rodvold KA, Spellberg B, Fowler VG. Antibacterial Resistance Leadership Group: Open for Business. Clinical Infectious Diseases 2014, 58: 1571-1576. PMID: 24610430, PMCID: PMC4017892, DOI: 10.1093/cid/ciu132.Peer-Reviewed Original ResearchConceptsAntibacterial Resistance Leadership GroupAntibacterial resistanceClinical research agendaPublic health threatClinical research opportunitiesInfection preventionClinical studiesAntimicrobial stewardshipClinical research proposalsInfectious diseasesClinical researchHealth threatNational InstituteInfectionMedical practiceHigh priority areasNegative bacteriaPositive bacteriaAllergyDiseasePrevention
2012
Controlling Antimicrobial Resistance through Targeted, Vaccine-Induced Replacement of Strains
Tekle YI, Nielsen KM, Liu J, Pettigrew MM, Meyers LA, Galvani AP, Townsend JP. Controlling Antimicrobial Resistance through Targeted, Vaccine-Induced Replacement of Strains. PLOS ONE 2012, 7: e50688. PMID: 23227198, PMCID: PMC3515573, DOI: 10.1371/journal.pone.0050688.Peer-Reviewed Original ResearchConceptsFirst clinical interventionImportant public health toolPan-resistant strainsInsufficient immune responsePublic health toolMulti-resistant strainsStaphylococcus aureus genotypesVaccine efficacyNosocomial outbreaksDrug treatmentImmune responseResistant serotypesFrequent reasonHypothetical vaccineVaccine developmentStrain replacementVaccineInfectious diseasesAureus genotypesClinical interventionsInfectionHealth toolsAntimicrobial resistanceIntervention strategiesSerotypes